RT Journal Article
SR Electronic
T1 Two independent introductions of SARS-CoV-2 into the Iranian outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.16.20229047
DO 10.1101/2020.11.16.20229047
A1 Fattahi, Zohreh
A1 Mohseni, Marzieh
A1 Jalalvand, Khadijeh
A1 Moghadam, Fatemeh Aghakhani
A1 Ghaziasadi, Azam
A1 Keshavarzi, Fatemeh
A1 Yavarian, Jila
A1 Jafarpour, Ali
A1 Mortazavi, Seyedeh elham
A1 Ghodratpour, Fatemeh
A1 Behravan, Hanieh
A1 Khazeni, Mohammad
A1 Momeni, Seyed Amir
A1 Jahanzad, Issa
A1 Moradi, Abdolvahab
A1 Tabarraei, Alijan
A1 Azimi, Sadegh Ali
A1 Kord, Ebrahim
A1 Hashemi-Shahri, Seyed Mohammad
A1 Azaran, Azarakhsh
A1 Yousefi, Farid
A1 Mokhames, Zakiye
A1 Soleimani, Alireza
A1 Ghafari, Shokouh
A1 Ziaee, Masood
A1 Habibzadeh, Shahram
A1 Jeddi, Farhad
A1 Hadadi, Azar
A1 Abdollahi, Alireza
A1 Kaydani, Gholam Abbas
A1 Soltani, Saber
A1 Mokhtari-Azad, Talat
A1 Najafipour, Reza
A1 Malekzadeh, Reza
A1 Kahrizi, Kimia
A1 Jazayeri, Seyed Mohammad
A1 Najmabadi, Hossein
YR 2020
UL http://medrxiv.org/content/early/2020/11/20/2020.11.16.20229047.abstract
AB The SARS-CoV-2 virus has been rapidly spreading globally since December 2019, triggering a pandemic, soon after its emergence, with now more than one million deaths around the world. While Iran was among the first countries confronted with rapid spread of virus in February, no real-time SARS-CoV-2 whole-genome tracking is performed in the country.To address this issue, we provided 50 whole-genome sequences of viral isolates ascertained from different geographical locations in Iran during March-July 2020. The corresponding analysis on origins, transmission dynamics and genetic diversity, represented at least two introductions of the virus into the country, constructing two major clusters defined as B.4 and B.1*. The first entry of the virus occurred around 26 December 2019, as suggested by the time to the most recent common ancestor, followed by a rapid community transmission, led to dominancy of B.4 lineage in early epidemic till the end of June. Gradually, reduction in dominancy of B.4 occurred possibly as a result of other entries of the virus, followed by surge of B.1.* lineages, as of mid-May.Remarkably, variation tracking of the virus indicated the increase in frequency of D614G mutation, along with B.1* lineages, which showed continuity till October 2020.According to possible role of D614G in increased infectivity and transmission of the virus, and considering the current high prevalence of the disease, dominancy of this lineage may push the country into a critical health situation. Therefore, current data warns for considering stronger prohibition strategies preventing the incidence of larger crisis in future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIranian Network for Research in Viral Diseases (INRVD) is acknowledged for help with the sample and data collection through its collaborative research centers and hospitals. This study was funded by Iran Vice deputy for Research and Technology at Iran Ministry of Health and Medical Education, grant number: 99/801/A/6/7586.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained the ethics committee approval from the corresponding committee in University of Social Welfare & Rehabilitation Sciences.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome of the sequence data is being uploaded in GISAID database and the rest is in process within 2 days. https://www.gisaid.org/